摘要
目的观察胰高糖素样激动剂1（GLP-1）的类似物利拉鲁肽治疗超重或肥胖的2型糖尿病的有效性及安全性。方法选择于2011—01—12～2013—01—20在本院接受治疗的超重2型糖尿病患者24例，所有患者在二甲双胍及吡咯列酮治疗的基础上加用利拉鲁肽，最初1周给予患者利拉鲁肽0．6mg晚上睡前皮下注射，第2周加量至1．6mg。观察患者的临床疗效，每2周随访1次，观察治疗12周后患者的FPG、2h-PPG、HbAlc、体重、收缩压及舒张压水平变化和不良反应情况。结果治疗12周后患者的FPG、2h-PPG、HbAIc、体重、收缩压及舒张压与治疗前比较，均有明显的改善，差异有统计学意义（P〈0．05）。无严重的不良反应。结论利拉鲁肽治疗超重或肥胖的2型糖尿病疗效肯定，安全，不增加体重，无明显不良反应的另一类糖尿病合适选择的治疗方法。
Objective To observe the efficacy and safety of the analogue of Glucagon-like peptide-1 （GLP-1） named liraglutide in the treatment of overweight or obese patients with type 2 diabetes. Methods A total of 24 overweight patients with type 2 diabetes were treated in the hospital on January 12, 2011 to January 20, 2013. All patients were treated with liraglutide as well as metformin and pioglitazone. Patients were injected with 0.6 mg liraglutide at bedtime at the first week and 1.6 mg at the second week. The clinical efficacy was observed. Follow-up was done once every 2 weeks. The FPG, 2 h-PPG, HbAlc, body weight, systolic, diastolic blood pressure levels and adverse reactions of patients were observed after 12 weeks of treatment. Results Compared with previous, the FPG, 2 h-PPG, HbAlc, body weight, systolic and diastolic blood pressure of patients were significantly improved after 12 weeks of treatment. The difference was statistically significant. There was no serious adverse reactions. Conclusion Liraglutide is effective and safe, without the risk of increasing the weight of the patients with type 2 diabetes, it is an ideal option when treats diabetes.
出处
《今日药学》
CAS
2014年第1期60-62,共3页
Pharmacy Today
